Shares of Alterity Therapeutics (ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy (MSA), a rare neurodegenerative disease. The study enrolled 10 participants with advanced MSA. Per the press company, interim analysis results from the open-label ATH434-202 study included clinical and biomarker data from seven participants who were treated with ATH43 ...